[go: up one dir, main page]

MA39248B1 - Anticorps anti-jagged1 et procédés d'utilisation correspondants - Google Patents

Anticorps anti-jagged1 et procédés d'utilisation correspondants

Info

Publication number
MA39248B1
MA39248B1 MA39248A MA39248A MA39248B1 MA 39248 B1 MA39248 B1 MA 39248B1 MA 39248 A MA39248 A MA 39248A MA 39248 A MA39248 A MA 39248A MA 39248 B1 MA39248 B1 MA 39248B1
Authority
MA
Morocco
Prior art keywords
methods
jagged1 antibodies
jagged1
antibodies
same
Prior art date
Application number
MA39248A
Other languages
English (en)
Inventor
Yan Wu
Christian W Siebel
Yvonne Chinn
Julie Q Hang
LAFKAS Daniel
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52574459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39248(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA39248B1 publication Critical patent/MA39248B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des anticorps anti-jagged1 et des procédés d'utilisation de ceux-ci.
MA39248A 2014-02-12 2015-02-11 Anticorps anti-jagged1 et procédés d'utilisation correspondants MA39248B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461939110P 2014-02-12 2014-02-12
PCT/US2015/015456 WO2015123325A1 (fr) 2014-02-12 2015-02-11 Anticorps anti-jagged1 et procédés d'utilisation correspondants

Publications (1)

Publication Number Publication Date
MA39248B1 true MA39248B1 (fr) 2018-10-31

Family

ID=52574459

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39248A MA39248B1 (fr) 2014-02-12 2015-02-11 Anticorps anti-jagged1 et procédés d'utilisation correspondants

Country Status (33)

Country Link
US (5) US9518121B2 (fr)
EP (3) EP3428190A1 (fr)
JP (1) JP6571115B2 (fr)
KR (2) KR20190114046A (fr)
CN (2) CN106068277B (fr)
AR (1) AR099465A1 (fr)
AU (3) AU2015217271B2 (fr)
BR (1) BR112016017986A2 (fr)
CA (2) CA2936565C (fr)
CL (1) CL2016002004A1 (fr)
CR (1) CR20160362A (fr)
DK (1) DK3105253T3 (fr)
EA (1) EA201691610A8 (fr)
ES (1) ES2685424T3 (fr)
HR (1) HRP20181359T1 (fr)
HU (1) HUE039940T2 (fr)
IL (1) IL246736B (fr)
LT (1) LT3105253T (fr)
MA (1) MA39248B1 (fr)
MX (1) MX2016010433A (fr)
MY (1) MY176855A (fr)
PE (1) PE20161335A1 (fr)
PH (2) PH12016501435A1 (fr)
PL (1) PL3105253T3 (fr)
PT (1) PT3105253T (fr)
RS (1) RS57608B1 (fr)
SG (2) SG10201808259TA (fr)
SI (1) SI3105253T1 (fr)
TR (1) TR201810635T4 (fr)
TW (2) TW201902515A (fr)
UA (1) UA121464C2 (fr)
WO (1) WO2015123325A1 (fr)
ZA (1) ZA201800315B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
WO2011009603A1 (fr) 2009-07-22 2011-01-27 Grünenthal GmbH Forme galénique inviolable pour des opioïdes sensibles à l’oxydation
AU2012292418B2 (en) 2011-07-29 2017-02-16 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
AU2012319150B2 (en) 2011-10-05 2017-08-17 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
AU2013225106B2 (en) 2012-02-28 2017-11-02 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
BR112015003032B1 (pt) 2012-08-13 2023-03-28 Genentech, Inc Anticorpos isolados, imunoconjugado, formulação farmacêutica e uso do anticorpo
MA38495A1 (fr) 2013-03-15 2017-08-31 Genentech Inc Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
SI3105253T1 (sl) 2014-02-12 2018-10-30 F. Hoffmann-La Roche Ag Protitelesa anti-Jagged1 in načini njihove uporabe
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
US10596200B2 (en) 2014-08-22 2020-03-24 Procella Therapeutics Ab Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells
DK3183337T3 (en) * 2014-08-22 2019-04-01 Procella Therapeutics Ab Use of Jagged 1 / Frizzled 4 as cell surface marker for isolation of human cardiac ventricular progenitor cells
WO2016170097A1 (fr) 2015-04-24 2016-10-27 Grünenthal GmbH Forme galénique inviolable avec libération immédiate et résistance à l'extraction par solvant.
JP7097814B2 (ja) 2016-02-19 2022-07-08 プロセラ セラピューティクス アーベー ヒト心室前駆細胞の生着のための遺伝子マーカー
US11026996B2 (en) * 2016-05-25 2021-06-08 The Trustees Of Columbia University In The City Of New York Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
US10508263B2 (en) 2016-11-29 2019-12-17 Procella Therapeutics Ab Methods for isolating human cardiac ventricular progenitor cells
JOP20190259A1 (ar) * 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
US11197884B2 (en) 2017-08-18 2021-12-14 Ionis Pharmaceuticals, Inc. Modulation of the notch signaling pathway for treatment of respiratory disorders
EP3487988B1 (fr) 2017-08-23 2020-01-01 Procella Therapeutics AB Utilisation de neuropilin-1 (nrp1) comme cellule surface identifiant pour l' isolation des celulles progeniteures des ventricles cardiacs
WO2019152599A1 (fr) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Anticorps monoclonaux d'acide nucléique ciblant pcsk9 et procédés d'utilisation
CN112129946A (zh) * 2020-08-16 2020-12-25 陆修委 无糖链型惰性蛋白封闭剂的制备方法及应用

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
EP0368684B2 (fr) 1988-11-11 2004-09-29 Medical Research Council Clonage de séquences d'immunoglobulines de domaines variables.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2026147C (fr) 1989-10-25 2006-02-07 Ravi J. Chari Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (fr) 1991-09-19 2003-11-11 Paul J. Carter Expression dans e. coli de fragments d'anticorps ayant au moins une cysteine presente sous forme de thiol libre. utilisation pour la production d'anticorps f(ab') bifonctionnels
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
US6004924A (en) 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
CA2163345A1 (fr) 1993-06-16 1994-12-22 Susan Adrienne Morgan Anticorps
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1998058964A1 (fr) 1997-06-24 1998-12-30 Genentech, Inc. Procedes et compositions concernant des glycoproteines galactosylees
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP2001521909A (ja) 1997-10-31 2001-11-13 ジェネンテク・インコーポレイテッド 糖タンパク質グリコフォームを含む方法及び組成物
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (fr) 1997-12-05 1999-06-17 The Scripps Research Institute Humanisation d'anticorps murins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2532910T3 (es) 1998-04-02 2015-04-01 Genentech, Inc. Variantes de anticuerpos y fragmentos de los mismos
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP1914244B1 (fr) 1999-04-09 2013-05-29 Kyowa Hakko Kirin Co., Ltd. Procédé pour la modulation de l'activité de molécules immunes fonctionnelles
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
DE60031793T2 (de) 1999-12-29 2007-08-23 Immunogen Inc., Cambridge Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EA013224B1 (ru) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Клетки, продуцирующие композиции антител
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
KR20040054669A (ko) 2001-08-03 2004-06-25 글리카트 바이오테크놀로지 아게 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003236015A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition
EP1498485A4 (fr) 2002-04-09 2006-09-06 Kyowa Hakko Kogyo Kk Cellules a genome modifie
CA2481920A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
WO2003085102A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
EP1502603A4 (fr) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk MEDICAMENT CONTENANT UNE COMPOSITION D'ANTICORPS APPROPRIEE AU PATIENT SOUFFRANT DE POLYMORPHISME FC gammma RIIIA
AU2003239966B9 (en) 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
US20040101847A1 (en) 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch2 expression
WO2004019921A2 (fr) 2002-08-29 2004-03-11 University Of Southampton Traitement de maladies hepatiques
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2301966A1 (fr) 2002-12-16 2011-03-30 Genentech, Inc. Variantes de l'immunoglobuline et leurs utilisations
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2005035586A1 (fr) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Composition proteique hybride
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
ME02332B (fr) 2003-11-05 2016-06-30 Roche Glycart Ag Molécules de liaison d'antigène avec affinité de liaison de récepteur Fc améliorée et fonction d'effecteur
AU2004316290C1 (en) 2003-11-06 2012-02-02 Seagen Inc. Monomethylvaline compounds capable of conjugation to ligands
EP1709150A4 (fr) 2003-11-26 2007-11-21 Health Research Inc Utilisation d'agents qui interferent avec la voie de transmission du signal notch pour le traitement des troubles plasmocytaires
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-ｐ-셀렉틴 항체
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
ES2669510T3 (es) 2004-09-23 2018-05-28 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2589374C (fr) * 2004-11-30 2016-05-03 Curagen Corporation Anticorps diriges contre la gpnmb et leurs utilisations
AT502055B1 (de) 2005-06-21 2007-11-15 Univ Wien Med Anti tumor medikament
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1952146A1 (fr) * 2005-11-10 2008-08-06 Brystol-Myers Squibb Company Methodes d'identification de composes inhibant un clivage de notch
EP1973951A2 (fr) 2005-12-02 2008-10-01 Genentech, Inc. Polypeptides de liaison avec des sequences de diversite limitees
WO2007130697A2 (fr) * 2006-01-05 2007-11-15 Genentech, Inc. Anticorps anti-ephb4 et procedes qui les utilisent
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
US20080241150A1 (en) 2006-05-15 2008-10-02 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20080226645A1 (en) * 2007-01-10 2008-09-18 Wyeth Methods and compositions for assessment and treatment of asthma
US20100119474A1 (en) * 2007-03-06 2010-05-13 Cornell University Chronic obstructive pulmonary disease susceptibility and related compositions and methods
EP2155249A4 (fr) * 2007-05-15 2011-11-16 Oncomed Pharm Inc Compositions et procédés pour le diagnostic et le traitement du cancer
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
EP2947097A1 (fr) * 2008-04-07 2015-11-25 Ablynx N.V. Séquences d'acides aminés dirigées contre les voies Notch et leurs utilisations
MY155603A (en) 2008-07-08 2015-11-13 Oncomed Pharm Inc Notch-binding agents and antagonists and methods of use thereof
WO2010032060A1 (fr) 2008-09-19 2010-03-25 Medimmune Llc Anticorps dirigés contre dll4 et leurs utilisations
RU2580029C2 (ru) 2008-10-01 2016-04-10 Дженентек, Инк. Антитела против notch2 и способы их применения
RU2636046C2 (ru) * 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
ES2580229T3 (es) 2009-09-30 2016-08-22 F. Hoffmann-La Roche Ag Anticuerpos antagonistas anti-Notch3 para el tratamiento de una leucemia de linfocitos T positiva a un inhibidor de la gamma-secretasa que no responde a un anticuerpo antagonista anti-Notch1
WO2011063237A2 (fr) * 2009-11-19 2011-05-26 Oncomed Pharmaceuticals, Inc. Agents de liaison au jagged et utilisations associées
WO2012106529A1 (fr) 2011-02-02 2012-08-09 The Trustees Of Princeton University Jagged1 en tant que marqueur et cible thérapeutique pour la métastase osseuse du cancer du sein
AU2012319150B2 (en) 2011-10-05 2017-08-17 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
IN2014MN02635A (fr) 2012-06-22 2015-10-16 Cytomx Therapeutics Inc
BR112015003032B1 (pt) 2012-08-13 2023-03-28 Genentech, Inc Anticorpos isolados, imunoconjugado, formulação farmacêutica e uso do anticorpo
GB201300706D0 (en) * 2013-01-15 2013-02-27 Cancer Rec Tech Ltd Antibody
WO2014141064A1 (fr) 2013-03-13 2014-09-18 Novartis Ag Molécules de liaison à notch2 pour le traitement de maladies respiratoires
MA38495A1 (fr) 2013-03-15 2017-08-31 Genentech Inc Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
SI3105253T1 (sl) 2014-02-12 2018-10-30 F. Hoffmann-La Roche Ag Protitelesa anti-Jagged1 in načini njihove uporabe
RU2017103289A (ru) 2014-07-11 2018-08-14 Дженентек, Инк. Ингибирование пути notch
JOP20190259A1 (ar) * 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1

Also Published As

Publication number Publication date
CN106068277B (zh) 2021-08-24
US11926674B2 (en) 2024-03-12
KR20160118348A (ko) 2016-10-11
CN111499741A (zh) 2020-08-07
SG11201606607UA (en) 2016-09-29
US10858440B2 (en) 2020-12-08
CA3045124A1 (fr) 2015-08-20
SG10201808259TA (en) 2018-10-30
US20150252117A1 (en) 2015-09-10
TR201810635T4 (tr) 2018-08-27
PH12020550781A1 (en) 2021-08-02
US9518121B2 (en) 2016-12-13
UA121464C2 (uk) 2020-06-10
ZA201800315B (en) 2020-05-27
EA201691610A1 (ru) 2016-11-30
AU2015217271A1 (en) 2016-08-11
BR112016017986A2 (pt) 2017-10-10
CA2936565C (fr) 2020-08-11
CN106068277A (zh) 2016-11-02
HRP20181359T1 (hr) 2018-10-19
CL2016002004A1 (es) 2017-01-20
PE20161335A1 (es) 2016-12-07
EP3105253B1 (fr) 2018-06-27
EP3105253A1 (fr) 2016-12-21
IL246736A0 (en) 2016-08-31
MX2016010433A (es) 2016-09-22
AU2018229549A1 (en) 2018-10-04
PH12016501435A1 (en) 2017-02-06
TW201613963A (en) 2016-04-16
WO2015123325A1 (fr) 2015-08-20
US20170137531A1 (en) 2017-05-18
US20180371098A1 (en) 2018-12-27
DK3105253T3 (en) 2018-09-03
US10011661B2 (en) 2018-07-03
CA2936565A1 (fr) 2015-08-20
SI3105253T1 (sl) 2018-10-30
LT3105253T (lt) 2018-09-10
TWI631135B (zh) 2018-08-01
EP3428190A1 (fr) 2019-01-16
EP3825332A1 (fr) 2021-05-26
IL246736B (en) 2020-09-30
JP6571115B2 (ja) 2019-09-04
TW201902515A (zh) 2019-01-16
HUE039940T2 (hu) 2019-02-28
US20240384000A1 (en) 2024-11-21
AU2020203547A1 (en) 2020-06-18
ES2685424T3 (es) 2018-10-09
PL3105253T3 (pl) 2018-12-31
RS57608B1 (sr) 2018-11-30
KR102030891B1 (ko) 2019-10-11
CR20160362A (es) 2016-09-20
PT3105253T (pt) 2018-10-04
EA201691610A8 (ru) 2018-05-31
AU2015217271B2 (en) 2018-10-25
MY176855A (en) 2020-08-24
AR099465A1 (es) 2016-07-27
US20210206871A1 (en) 2021-07-08
KR20190114046A (ko) 2019-10-08
JP2017512067A (ja) 2017-05-18

Similar Documents

Publication Publication Date Title
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
ZA202107931B (en) Anti-tau antibodies and methods of use
MY191169A (en) Anti-fcrh5 antibodies
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
MX2017000419A (es) Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
MX2024000300A (es) Anticuerpos antitau y metodos de uso.
MY193661A (en) Anti-tim3 antibodies and methods of use
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
WO2018081648A8 (fr) Anticorps anti-mic et méthodes d'utilisation
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MX2019006330A (es) Anticuerpos anti-tau y metodos de uso.
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX354303B (es) Anticuerpos de anti-biotina y metodos de uso.
MA40512A (fr) Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MA39355A1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA39141A1 (fr) Anticorps anti-tau(ps422) humanisés et leurs méthodes d'utilisation
NZ744340A (en) Anti-jagged1 antibodies and methods of use